Capricor Therapeutics Inc

Research Capricor Therapeutics Inc (CAPR) on Bullrun: market cap USD 1.38B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCAPR
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 1.38B
• Financial periodFY2025
• Revenue growth-100.0%
• Net income-USD 105.04M
• Free cash flow-USD 72.72M

Valuation Snapshot

latest market cap is USD 1.38B.

About Capricor Therapeutics Inc

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2;

Frequently asked questions

What is Capricor Therapeutics Inc's market cap?

Capricor Therapeutics Inc's market capitalization is USD 1.38B.

What does Capricor Therapeutics Inc do?

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.